Survivin, a member of the inhibitors of apoptosis protein family, plays important roles in cell proliferation and survival and is highly expressed in various malignancies, including leukemias.
Abstract
Survivin, a member of the inhibitors of apoptosis protein family, plays important roles in cell proliferation and survival and is highly expressed in various malignancies, including leukemias.
To better understand its role in AML, we profiled survivin expression in samples obtained from 511 newly diagnosed AML patients and in CD34 + 
38
-AML stem/progenitor cells using a validated reverse-phase protein array and correlated its levels with clinical outcomes and with levels of other proteins in the same sample set. We found that survivin levels were higher in bone marrow than in paired peripheral blood leukemic cells (n=140, P=0.0001) and that higher survivin levels significantly predicted shorter overall (P=0.016) and event-free (P=0.023)
survival in multivariate Cox model analysis. Importantly, survivin levels were significantly higher in CD34 + 38 -AML stem/progenitor cells than in bulk blasts and total CD34 + AML cells (P<0.05). Survivin expression correlated with the expressions of multiple proteins involved with cell proliferation and survival. Particularly, its expression strongly correlated with HIF1α in the stem/progenitor cell compartment. These results suggest that survivin is a prognostic biomarker in AML and that survivin, which is overexpressed in AML stem/progenitor cells, remains a potentially important target for leukemia therapy.
Introduction
Resistance to chemotherapy, the primary treatment for acute myeloid leukemia (AML) is a major obstacle to cure of these patients and is often attributed to the deregulation of apoptosis in AML cells, particularly in AML stem cells. Although cytogenetic analysis at the time of diagnosis provides important prognostic information, molecular markers have also been used to provide further prognostic information and direct patients to targeted treatment options, especially for patients with normal cytogenetics [1] [2] [3] . Thus, identifying deregulated apoptosis regulators that may be prognostic markers and understanding their roles in cell death and chemoresistance may facilitate the selection of treatment options and benefit patients.
Survivin, a member of the inhibitors of apoptosis (IAP) protein family, is one of the most frequently upregulated transcripts in cancer but is expressed at low or undetectable levels in many normal adult tissues 4 . Survivin in malignant cells is upregulated by multiple signaling pathways and by tumor microenvironments including PI3K, MAPK, STAT3, Wnt/β-catenin, hypoxia, angiogenesis, and NF-κB signaling pathways [5] [6] [7] [8] [9] [10] [11] . Survivin is part of the Aurora Bsurvivin-INCENP-Borealin/Dasra B complex, the chromosomal passenger essential for cell cycle progression and cytokinesis 12, 13 . Its roles in regulating cell proliferation and cell death and its differential expression in many cancers make survivin a promising therapeutic target and a potential prognostic marker [14] [15] [16] [17] . Overexpression of survivin has been identified in a number of hematological malignancies 18 . We found that survivin is highly expressed in AML blasts and its expression is regulated by hematopoietic cytokines through MAPK and PI3K signaling 5 . In addition, we found that targeting survivin by antisense oligonucleotide (ASO) induces cell proliferation defects and subsequent cell death in AML cells 19 . Recently, survivin expression has
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From also been found to be stimulated by the AML1/ETO fusion protein in AMLs carrying the t(8;21)(q22;q22) chromosome translocation 20 . We have also reported that survivin is regulated through Bcr-Abl/MAPK signaling in chronic myeloid leukemia (CML) cells, and that targeting survivin overcomes imatinib resistance, decreases colony formation in samples from CML patients in blast crisis, and increases imatinib sensitivity in imatinib-responsive CML cells 21 .
Furthermore, the role of survivin in promoting leukemogenesis was supported by a recent study
showing that overexpression of survivin initiates hematologic malignancies in transgenic mice 22 .
High levels of survivin have been reported to predict unfavorable prognoses in a number of hematologic malignancies [23] [24] [25] [26] . Although survivin was reported to be highly expressed in AML, its prognostic impact is not clearly defined. Some found that survivin predicts poor clinical outcomes, others did not [26] [27] [28] . This lack of a definitive answer is largely related to small sample sizes and different ways of measuring survivin levels such as protein versus RNA.
Reverse-phase protein array (RPPA) is a robust and reproducible high-throughput proteomics system that can quantitatively determine protein expression levels in large sample sets and requires only small amounts of protein. Our group has established RPPA and demonstrated that it is a valuable tool for the functional profiling of protein expression in AML [29] [30] [31] . To better understand the roles of survivin in AML, we took advantage of this state-of-art novel technology 29, 30 , determined expression levels of survivin and of 206 additional proteins of interest in samples obtained from 511 patients newly diagnosed with AML and analyzed the correlation of survivin levels with clinical outcomes and with the levels of other proteins. AML stem cells, which give rise to leukemic blasts, are known to be more resistant to therapy and responsible for disease relapse. We therefore also measured survivin levels in CD34 +
-AML
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From stem/progenitor cells taking advantage of the minimal sample size requirement of RPPA and correlated survivin with additional 120 other proteins probed in the same data set. We found that survivin is a prognostic marker in AML and that its expression is higher in the AML stem/progenitor cell compartment than in blasts and total CD34 + AML cells and correlated with multiple proteins involved in cell proliferation and survival.
Materials and Methods
Patient population: The patient population was the same as previously described 31 . Of the 511 AML patients, 415 were treated at MD Anderson and were evaluable for outcome.
Among the treated patients, 277 received regimens that contained high-dose Ara-C, 35 received
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From standard-dose Ara-C, and 8 received low-dose Ara-C. Most of the Ara-C-treated patients also received other treatments. A variety of regimens were given to the other 95 patients.
Sample collection, sample preparation, and RPPA: Proteomic profiling was performed on samples from patients with AML as previously described 31 . RPPA was carried out following the methods and validation procedures described fully in previous publications 29, 30 . Briefly, patient samples were printed onto the slides in five serial dilutions along with controls for normalization and expression. Statistical analysis: Supercurve algorithms were used to generate a single value from the five serial dilutions 34 . The loading control 35 clustering, and principal component analyses were performed as described previously 29, 30 .
Associations between survivin expression levels and categorical clinical variables were assessed in R using standard t tests, linear regression, or mixed-effects linear models. Associations between the protein level and continuous variables were assessed using Pearson and Spearman correlation and linear regression analysis. Bonferroni corrections were performed to account for the multiple statistical parameters used for calculating statistical significance. A Cox proportional hazards regression model (1972) was used to evaluate the ability of patient prognostic variables and survivin to predict overall survival (OS) and event free survival (EFS).
Patients with missing data were excluded from the analysis. A Kaplan-Meier plot was generated to evaluate differences in OS and EFS between the two groups separated by the median value of Outcome analyses and multivariate analyses were carried out using the software R version, 2.12.1 36 .
Results

Survivin is differentially expressed in BM and PB samples obtained from newly diagnosed AML patients
We determined survivin expression by RPPA in the samples obtained from 511 newly diagnosed AML patients ( Table 1 ) and found that it was variably expressed. Paired BM and PB were available from 140 patients. To assess whether survivin levels differ depending on the source of the samples, we compared the levels of survivin in the 140 paired BM and PB samples using paired t-test and Pearson's product-moment correlation analysis and found that survivin levels were significantly higher in samples from BM than from PB ( Figure 1 ) as demonstrated by both waterfall plot (P=0.0001, Figure 1A ) and scatter plot (correlation coefficient = 0.24, P=0.004, Figure 1B ) consistent with its function in cell proliferation and its induction by growth factors and hematopoietic cytokines.
Correlation of survivin expression with clinical characteristics of patients
Survivin levels were determined from samples taken at diagnosis and relapse, and the levels were compared using paired t-test and Pearson's product-moment correlation analysis. Among the 47 cases with paired diagnosis and relapse samples, there was no consistent pattern of change in survivin levels (Figure 2 ) as demonstrated by both waterfall plot (P=0.64, Figure 2A ) and scatter plot (correlation coefficient = -0.017, P=0.908, Figure 2B ). In most cases, the expression levels in the paired samples were within two-fold of each other. However, more pairs were found to have higher survivin levels at relapse than at diagnosis (28 pairs versus 19 pairs; Figure 2A ).
Survivin expression did not correlate with any demographics of patients and clinical characteristics shown in platelet count, or hemoglobin levels. Survivin levels also did not correlate with whether the patients had a history of prior malignancy, chemo-, or radiation therapy. By univariate analysis, although high survivin levels had a trend to be associated with worse OS or EFS, these associations were not statistically significant, using either Kaplan-Meier plots (P=0.14 and P=0.23, respectively, with high and low survivin expression level groups defined by the median value) (Supplemental Figure 1) or a Cox regression model (hazard ratio HR=1.08, P=0.18 and HR=1.10, P=0.12, respectively, for one unit increase in the continuous survivin expression level) (Supplemental Table 1 ).
Survivin expression is an independent predictor of OS and EFS in multivariate analysis
To determine the prognostic impact of survivin levels in AML in multivariate analysis, Cox proportional hazards modeling was performed based on the stepwise model selection method using survivin levels as a continuous variable. Results showed that survivin was a significant factor for both OS (P=0.016) and EFS (P=0.023). As demonstrated in Table 2.1 and Table 2 and EFS (P=0.017) (Supplemental Table 3 ). Intensively treated group was patients who received the high dose Ara-C (HDAC) based regimens including HDAC, HDAC plus fludarabine, HDAC plus anthracycline, and HDAC plus non-anthracycline and standard Ara-C plus anthracycline.
Less intensively treated group was patients who received low dose Ara-C, demethylating agents, histone deacetylating agents, and various targeted therapies. Next, we analyzed survivin levels and clinical outcomes considering stem cell transplant as a censoring event. Sixty-six patients underwent stem cell transplant: syngeneic, 1; related donors, 39; and unrelated donors, 26.
Again, survivin was highly prognostic for both OS (P=0.007) and EFS (P=0.008) (Supplemental Table 4 ). Because the survivin levels in BM and PB were different, we also analyzed the data 
Correlation of survivin expression with the expression of other proteins
In addition to survivin, the same set of samples was also probed for 206 (Supplemental Table 5) other proteins for samples from 511 newly diagnosed AML patients and 120 (Supplemental Table 6 ) proteins for CD34 + 38 -cells isolated from blasts of 37 AML patients, enabling us to correlate survivin expression levels with the levels of various proteins. As shown in Figure 4 , survivin expression correlated with the expressions of multiple proteins. Figure 4A shows the results in samples from 511 newly diagnosed AML patients. Survivin levels positively correlated with levels of various cell proliferation related proteins (pink, Figure 4A ), such as cyclins, cyclin-dependent kinases, MSI2, and catenins consistent with its function in cell proliferation.
Survivin levels also significantly correlated with the levels of proteins in the PI3K signaling pathway (red, Figure 4A ): positively with PI3Kp110, phosphorylated mTOR, p70S6K, and BADp155, and negatively with PTEN in agreement with the induction of survivin by PI3K signaling as described by us previously 5 . Surprisingly, survivin levels correlated negatively with levels of several proteins in the MAPK signaling pathway (blue, Figure 4A ) and proteins involved with cell migration/adhesion such as integrin B3, VASP, fibronectin, and stathmin (green, Figure 4A ) and FAK (R = 0.19 and P < 0.0001, not shown). Figure 4B shows proteins whose expression levels significantly correlated with survivin levels in CD34 Figure 4B ). It positively correlated with multiple cyclin-dependent kinases, cyclins (pick, Figure 4B ), but negatively correlated with cyclin B1 (green, Figure 4B ). It also Figure 4B ). Specifically, levels of survivin strongly correlated with HIF1α levels (cyan, Figure 4B ), in agreement with survivin regulation by the hypoxia microenvironment and the highly hypoxic stem cell niche 38 . Survivin also strongly correlated with several proteins important for stem cell functions, such as Myc and Mcl-1 (purple open boxes, Figure 4B ). Note that survivin expression was correlated with approximately 200 proteins on samples from 511 newly diagnosed AML patients and with 120 proteins for CD34 + 38 -cells isolated from blasts of 37 AML patients. Therefore, some proteins correlated with survivin in the former but not in the latter samples, because they were not included in the stem cell sample set or the sample size for the CD34 + 38 -group was too small.
Discussion
In this study, we found that survivin levels were significantly higher in CD34 In the stem/progenitor cell compartment its expression strongly correlated with HIF1α. We also found that survivin levels were higher in BM than in paired PB leukemic cells and that higher survivin levels significantly predicted shorter OS and EFS. These findings support the roles of survivin in cell proliferation and survival and suggest that survivin expression predicts poor clinical outcome in AML and that survivin plays important roles in AML stem cells.
Survivin levels were found to be higher in BM than in PB in 140 paired samples from newly diagnosed AML patients. Blasts in the BM and PB reside in very different microenvironments, A recent study in rectal cancer showed that higher survivin expression correlated with advanced disease, and failure to downregulate survivin following neoadjuvant radiochemotherapy was associated with distant metastases and shorter survival 39 . Among the 47 cases with paired diagnosis and relapse samples in the current study, we did not observe a consistent pattern of change in survivin levels (P=0.64) and saw both increases and decreases in survivin levels in the relapsed samples. However, we did observe that survivin levels were more likely to be increased (n=28) than decreased (n=19) at relapse. Thus, more paired samples are needed to determine whether survivin levels are different between diagnosis and relapse samples in AML.
It was reported that survivin predicts poor clinical outcome in different hematological malignancies including AML [23] [24] [25] [26] [27] [28] . We previously determined survivin expression by western blot in 116 AML patient samples 27 . Although log-rank tests and Cox regression analysis showed that the risk of mortality increased as the survivin level increased, it did not reach statistical significance. Using Martingale residual analysis, we identified a small group of patients with very high survivin levels who were at high risk for death, but this group was too small for the results to be statistically significant 27 . In addition, not all 116 samples were obtained from newly diagnosed patients. In the current study, we took advantage of the robust RPPA method to profile Correlative studies showed that survivin levels correlated with multiple proteins related to survivin regulation and function. Correlation of survivin expression with PI3K signaling supports the regulation of survivin by PI3K signaling and its prosurvival role. Correlation of survivin with cyclin-dependent kinases and cyclins supports cell cycle-dependent regulation of survivin and its role in cell proliferation as survivin is known to be essential for cell cycle progression and cytokinesis. Correlation of survivin with catenins supports the regulation of survivin by wnt/β-catenin pathway 10, 11 . Correlation of survivin with HIF1α in AML stem/progenitor cells is consistent with regulation of survivin by hypoxia 9 . It is interesting that survivin positively correlated with MSI2, a protein expressed in hematopoietic stem cells (HSC) and essential for HSC self-renewal and long-term hematopoietic engraftment 40 . A recent study demonstrated that MSI2 protein expression predicts unfavorable outcome in AML 41 . It was surprising that survivin levels negatively correlated with MAPK signaling and multiple proteins related to cell migration/adhesion since we and others have showed that survivin expression is induced by MAPK/ERK signaling 5 and that survivin was reported to activate NF-κB in cooperation with XIAP, leading to fibronectin gene expression, and regulate metastasis in epithelial tumors 42 . We believe that the correlation results are valid as survivin was negatively correlated with not just one but multiple proteins in the MAPK signaling pathway and various proteins related to cell migration/adhesion. The negative correlation of survivin with MAPK signaling and members of cell adhesion/migration proteins does not imply that survivin is not regulated by MAPK signaling or that survivin does not affect cell adhesion and migration. In addition, although survivin was reported to be upregulated by FLT3-ITD and regulate the expansion of FLT3-ITDtransformed hematopoietic progenitor cells with self-renewal capacity and development of FLT3-ITD acute leukemia in mice 43 , we did not find survivin levels correlated with FLT3-ITD mutation status. Clearly, survivin's relation with these proteins is not simply one-directional, but it may involve cross talk, feedback, and/or other unknown mechanisms. Survivin was also found to correlate positively with p21, p27, and p53. However, the phosphorylation status of p21 and p27 is unknown and mutation status of p53 is not completely determined in these patient samples. Although the correlation study will help us to understand the regulation of survivin and provide a basis for optimal combinations to target various survival pathways for therapies, more mechanistic studies are needed to better understand the regulation of survivin and interactions of survivin with other proteins and signaling pathways in AML cells.
AML is a stem cell disease, and the ineffectiveness of chemotherapy in eradicating leukemic stem cells contributes at least in part to the inevitable relapse of AML. In this regard, our finding that survivin levels are higher in the CD34 + 38 -compartment of AML is of particular interest. In conclusion, we demonstrated that survivin is an adverse predictor of survival in AML.
Survivin is overexpressed in AML stem/progenitor cells and its expression correlates with the expression of multiple proteins participating in cell growth and survival. Given survivin's role in cell proliferation and apoptosis suppression, survivin remains a potentially important target for leukemia therapy. We thank Deanna Alexander for helping with the manuscript preparation.
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